Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 17363540)

1.

Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy.

Lee KC, Hamstra DA, Bhojani MS, Khan AP, Ross BD, Rehemtulla A.

Clin Cancer Res. 2007 Mar 15;13(6):1839-46.

2.

Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil.

Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T.

Eur J Cancer. 2002 Jan;38(1):167-76.

PMID:
11750847
3.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells.

Dorsey JF, Mintz A, Tian X, Dowling ML, Plastaras JP, Dicker DT, Kao GD, El-Deiry WS.

Mol Cancer Ther. 2009 Dec;8(12):3285-95. doi: 10.1158/1535-7163.MCT-09-0415. Epub .

7.

The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth.

Nozawa F, Itami A, Saruc M, Kim M, Standop J, Picha KS, Cowan KH, Pour PM.

Pancreas. 2004 Jul;29(1):45-52.

PMID:
15211111
8.
9.
10.

Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.

Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, Damdinsuren B, Ota H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Yagita H, Monden M.

Clin Cancer Res. 2004 Dec 1;10(23):7884-95.

11.

Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.

Pasello G, Urso L, Silic-Benussi M, Schiavon M, Cavallari I, Marulli G, Nannini N, Rea F, Ciminale V, Favaretto A.

J Thorac Oncol. 2014 Jul;9(7):1008-17. doi: 10.1097/JTO.0000000000000198.

PMID:
24922007
12.

Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.

Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, Bedi A.

Cancer Res. 2004 Dec 15;64(24):9105-14.

13.

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.

Cancer Res. 2004 Jul 15;64(14):4900-5.

14.

TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.

Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, Lazar AJ, Hayes-Jordan A, Liu K, Bankson J, Hazle JD, Lev D.

Clin Cancer Res. 2010 May 1;16(9):2591-604. doi: 10.1158/1078-0432.CCR-09-2443. Epub 2010 Apr 20. Erratum in: Clin Cancer Res. 2015 Apr 1;21(7):1773.

15.

Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.

Zhou L, Wang W, Dicker DT, Humphreys RC, El-Deiry WS.

Cancer Biol Ther. 2011 Aug 15;12(4):335-48. Epub 2011 Aug 15.

16.

Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.

Kim SM, Woo JS, Jeong CH, Ryu CH, Jang JD, Jeun SS.

Stem Cells Transl Med. 2014 Feb;3(2):172-82. doi: 10.5966/sctm.2013-0132. Epub 2014 Jan 16.

17.

Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.

Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Möller P, Gschwend JE, Simmet T, Debatin KM, Fulda S.

Cancer Res. 2009 Mar 15;69(6):2425-34. doi: 10.1158/0008-5472.CAN-08-2436. Epub 2009 Mar 3.

18.

Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.

Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin KM, Fulda S.

Cancer Res. 2008 Oct 1;68(19):7956-65. doi: 10.1158/0008-5472.CAN-08-1296.

19.

CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.

Röhn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, Weller M.

Oncogene. 2001 Jul 12;20(31):4128-37.

20.

Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.

Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.

Cancer Res. 2005 Jun 1;65(11):4799-808.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk